Drug-drug Interaction Study of KL1333 in Healthy Subjects
Status:
Completed
Trial end date:
2020-12-17
Target enrollment:
Participant gender:
Summary
A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate
the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and
CYP3A4 in Healthy Subjects